CD38 and B-cell chronic lymphocytic leukemia: For instance, in chronic lymphocytic leukemia CD38+ clones in the TME have a survival advantage over CD38- clones as they depict higher migration towards the chemokine CXCL12 resulting in enhanced homing to lymphoid tissue and improved survival with higher expression of VEGF and antiapoptotic protein Mcl1[44].